Carlos Garcia was appointed to the Board of Trustees January 2018. Recently retired from Novartis Pharmaceuticals after 16 years of service, he is currently a board member, investor and advisor for startup health ventures.
With over 30 years’ experience in senior roles at two Fortune 100 Pharma companies across six continents and more than 100 countries, his most recent role was that of President, Asia, Africa and Middle East Countries (AMAC) for Novartis. Prior to leading the AMAC, he was President, Latin America and Canada (LACan); and for 12 years, he led this 40-country division, which was routinely recognized as the best place to work, to launch a career and the most ethical company. Novartis Latin America became the fastest growing MNV among the top 10 from 2008-2012. Mr. Garcia sponsored and led the largest pharmaceutical loyalty program in the world in Brazil with over four million active patients, as well as several other initiatives for Novartis, including the Access to Medicines and the Malaria Initiatives.
Over a 20-year period, he held various leadership positions at Eli Lilly, which included President, Central and Eastern Europe (Vienna), General Manager for Mexico, Argentina, and Philippines, CFO Colombia and several sales and marketing assignments in the United States. He has held senior positions on several boards, among them being the International Federation of Pharmaceutical Manufactures (IFPMA), Federacion Internacional de la Industria Farmaceutica LatAm (FIFARMA), International Section of PhRMA, as well as pharma associations, including PhAH Philippines.
Mr. Garcia received a degree in Industrial Engineer from Universidad del Norte, the Barranquilla, Colombia and holds two MBA’s, from Cornell University in New York, United States, and from Katholieke Universiteit te Leuven, Belgium.